Abstract 2140: Beyond antibodies and CAR-T: CC312, a first-in-class, anti-CD19, anti-CD3, anti-CD28 trispecific antibody in treatment with relapsed and/or refractory B-cell malignancies

Authors: Yingfeng Huang, Xiaofang Zhang, Ruixia Zhang, Zhen Jing, Caizhi Zhao, Fangfang Pan, Beibei Zheng, Ruixue Dai, Yingying Yang, Li Zeng

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-2140

Source: Full article


Abstract

Background: